The preliminary data to date has indicated that Triolex is safe and well tolerated at all doses studied. In addition, the preliminary data thus far suggest that Triolex reduces fasting blood glucose levels and improves insulin sensitivity as evaluated through euglycemic/hyperinsulinemic clamps, an industry standard measurement for assessing whole body glucose metabolism and to test compounds as potential insulin sensitizers for the treatment of type 2 diabetes.
Jaime Flores-Riveros, vice president of metabolism and endocrinology at Hollis-Eden, said: “We are very pleased to see positive preliminary data from this clinical trial even at some of our lowest doses tested and with only 28 days of dosing. Furthermore, to see a drop in the inflammatory mediators from the peripheral blood mononuclear cells is exciting because this population contains the subset of cells associated with fatty acid induced inflammation that leads to insulin resistance.”